-
Axitinib (AG 013736) Assay Workflow Guide
2026-09-16
A practical guide to using Axitinib (AG 013736) in VEGFR-focused angiogenesis inhibition assays, cancer cell response studies, and xenograft-aligned workflows. It combines concentration planning, dual viability-and-death readouts, and troubleshooting strategies to distinguish pathway suppression from nonspecific cytotoxicity.
-
Carboplatin Workflows for Resistance Research
2026-09-16
Build reproducible Carboplatin cytotoxicity assays while distinguishing DNA damage from cancer stem-cell-mediated resistance. This workflow connects concentration-response testing with the IGF2BP3–FZD1/7 mechanism reported in triple-negative breast cancer.
-
AG-221 (Enasidenib): Reading 2-HG Biology
2026-09-15
AG-221 (Enasidenib) is more than an IDH2 inhibitor: it is a mechanistic probe for connecting 2-hydroxyglutarate reduction with leukemia-cell state and metabolic dependency. This guide develops an assay-centered framework informed by recent CD44 research without duplicating conventional resistance or workflow summaries.
-
Axitinib: From VEGFR Potency to Assay Meaning
2026-09-15
Axitinib (AG 013736) is examined through a dual-metric framework that separates growth inhibition from cell death. This article translates VEGF pathway pharmacology into more rigorous angiogenesis assays, cancer biology research, and xenograft interpretation.
-
BCL-XL inhibitor A-1155463: From Mechanism to Translation
2026-09-14
A mechanism-first perspective on how A-1155463 can help translational researchers interrogate apoptotic dependence, drug resistance, and therapeutic vulnerability across glioblastoma, solid tumors, and hematological malignancies. The article connects published glioblastoma biology with practical experimental design while clearly distinguishing tool-compound evidence from clinical readiness.
-
CPI-613: Mitochondrial Assay Workflows
2026-09-14
CPI-613 enables a practical bridge between mitochondrial metabolism, apoptosis, and chemotherapy-sensitization assays. This workflow-oriented guide shows how to test 6,8-bis(benzylsulfanyl)octanoic acid in tumor cells and mechanism-focused cholangiocarcinoma models while controlling solubility, vehicle, and endpoint variability.
-
Sunitinib: Multi-Targeted RTK Inhibitor
2026-09-13
Sunitinib is an orally bioavailable, multi-targeted receptor tyrosine kinase inhibitor with nanomolar activity against VEGFR, PDGFR, KIT, and RET. Research applications include tumor angiogenesis, apoptosis induction in renal cell carcinoma, cell cycle arrest at G0/G1 phase, and nasopharyngeal carcinoma research.
-
Coelenterazine for AVP Reporter Decisions
2026-09-12
Coelenterazine is a luminescent enzyme substrate that can connect luciferase reporter output with oxidative biology. This article uses the liraglutide–AVP study as a decision framework for separating secretion, signaling, and ROS measurements in advanced assay design.
-
RNA Pol II Degradation Activates Programmed Cell Death
2026-09-11
Harper et al. show that RNA polymerase II inhibition kills cells through an active apoptotic program triggered by depletion of hypophosphorylated RNA Pol IIA, rather than through transcriptional collapse alone. Their PDAR framework provides a mechanistic lens for interpreting transcription-targeting drugs and for designing cancer research experiments that distinguish loss of transcription from loss of the polymerase itself.
-
Ranolazine: A Mechanistic Guide for Cardiac Assays
2026-09-11
Ranolazine is an anti-ischemic agent whose late sodium current inhibition and metabolic actions can be separated through mechanism-aware assay design. This guide also explains how cardiac and hepatic readouts should—and should not—be interpreted alongside HBV-associated TBK1, interferon, and autophagy biology.
-
CB-839 (Telaglenastat) Experimental Workflow
2026-09-10
Build a practical GLS1-focused workflow with CB-839 (Telaglenastat) for glutaminolysis inhibition assays, metabolite tracing, viability studies, and autophagy analysis. The approach also helps connect direct GLS1 blockade with PRMT5-linked metabolic vulnerability while separating mechanism, model-specific response, and translational evidence.
-
Epacadostat (INCB024360) for IDO1 Research
2026-09-10
Epacadostat, also called INCB024360, is an orally active and selective IDO1 inhibitor for immuno-oncology research. Product data report nanomolar inhibition of recombinant human IDO1 and IFN-γ-stimulated cancer-cell IDO1 activity, while standardized whole-blood stimulation provides a complementary framework for studying metabolism-dependent cytokine responses.
-
One-step TUNEL FITC Apoptosis Detection Kit
2026-09-09
The One-step TUNEL FITC Apoptosis Detection Kit uses FITC-labeled dUTP incorporation to mark DNA strand breaks associated with apoptosis in tissue sections and cultured cells. The K1133 workflow supports fluorescence microscopy and flow cytometry, but TUNEL signal should be interpreted with morphological, biochemical, or viability measurements.
-
Palonosetron: From Receptor Kinetics to Translation
2026-09-09
Palonosetron hydrochloride is more than a long-acting antiemetic. Its subtype-selective pharmacology, ligand-dependent dissociation kinetics, and distinct transporter activity create a practical framework for connecting receptor mechanism with translational oncology research, assay design, and chemotherapy-induced nausea and vomiting prevention.
-
Perifosine: A Stress-Resolved Akt Assay Strategy
2026-09-08
Perifosine (KRX-0401) can do more than inhibit Akt: it enables a stress-resolved framework linking survival signaling, apoptosis, and treatment response. This article translates cerebral ischemia research into practical oncology assay decisions without overstating cross-domain evidence.